Draft:Mark Rowland Hutchinson
| Submission declined on 31 July 2024 by SafariScribe (talk). This submission does not appear to be written in the formal tone expected of an encyclopedia article. Entries should be written from a neutral point of view, and should refer to a range of independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid peacock terms that promote the subject. This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs to
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Mark Hutchinson | |
|---|---|
 Mark Hutchinson in 2024 | |
| Born | Mark Rowland Hutchinson 1978 (age 45–46) |
| Nationality | Australian |
| Alma mater | University of Adelaide (PhD) |
| Scientific career | |
| Fields | |
| Institutions | |
| Thesis | Opioids and immune function: The role of non-classical opioid receptors and the association with pain perception (2004) |
| Website | https://researchers.adelaide.edu.au/profile/mark.hutchinson |
Mark Rowland Hutchinson (born 1978) is an Australian scientist and academic who is recognised for his significant contributions to the field of neuroimmunology, particularly in the areas of pain, stress, and drug dependence.[1] He is currently a Professor in the School of Biomedicine at the University of Adelaide and the Interim Director of the Institute for Photonics and Advanced Sensing.[1]. He was formally the Director of the ARC Centre of Excellence for Nanoscale BioPhotonics.[1] He leads the Neuroimmunopharmacology laboratory and is the Lead of the Human Integrated Sensory System Program for the Defence Science Technology Group.[1] He is currently the PresidentSTA-admin (2021-11-25). "Science innovator and entrepreneur Mark Hutchinson starts as STA President". Science and Technology Australia. Retrieved 2023-05-02. of Science and Technology Australia, member of the Australian Research Council CEO Advisory committee"Appointment of 2021 ARC Advisory Council". ARC Media. 22 October 2021. Retrieved 2 May 2023., founding member of the Defence Science Technology Group Advisory Council responsible for overseeing the CBRN STaR Shot, co-chair of the SABRE (Safeguarding Australia through Biotechnology Response and Engagement) Alliance "Biotech alliance announced at ADSTAR 2022". Defence Media. 22 July 2022. Retrieved 2 May 2023., founding executive member of The Animal Welfare Collaborative (TAWC), chair of the Australian Pain Solutions Alliance steering committee, and chair of the Davies Livestock Research Centre Advisory Board.[1]
He was also one of three eminent academics reviewing the ARC Federal Legislation.[1] He was recently appointed to the National Science and Technology Council [2] and serves on the Australia's Economic Accelerator Advisory Board.[3][4]
Education
[edit]Hutchinson received a Bachelor of Science degree with majors in Immunology, Microbiology, and Pharmacology from the University of Adelaide.[1] This was followed by a first class Honours in Pharmacology.[1] He then pursued a Doctor of Philosophy degree in Medicine with a focus on Pharmacology from the same university in 2004.[1] His is passionate about life long learning and has recently received training in not-for-profits board of directors from the Australian Institute for Company Directors.[1]
Career and research
[edit]Hutchinson's research career began in 2004 as a postdoctoral researcher at the University of Colorado Boulder with Distinguished Professors Linda Watkins and Steven Maier.[1] Here we was supported by an American Australian Association Merck Company Foundation Fellowship "lumen -- Scientist rubs shoulders with celebrities". www.adelaide.edu.au. Retrieved 2023-05-02. and an NHMRC CJ Martin Fellowship "Strong drugs without the addiction". www.adelaide.edu.au. Retrieved 2023-05-02.. In 2009 he returned to the University of Adelaide in the Faculty of Health and Medical Research and established the Neuroimmunopharmacology Laboratory.[1] He was awarded an Australian Research Council Australian Research Fellowship in 2011, and an ARC Future Fellowship in 2018.[1] In 2014 he became the Director of the ARC Centre of Excellence for Nanoscale BioPhotonics.[1]
The Neuroimmunopharmacology Laboratory he leads is a world-leading research team, whose main focus is to develop innovative technologies that allow for the early diagnosis and treatment of neurological diseases.[1] Their innovation centre focuses on translational science, developing biomarkers and wearables for real-time monitoring and precision medicine in humans and animals.[1]
Publications
[edit]
Hutchinson has published over 240 papers"ORCID". orcid.org. Retrieved 2023-05-02. including refereed journal articles and conference papers. These have led to over 13000 citations in journals and refereed conference proceedings "Prof Mark R Hutchinson". scholar.google.com.au. Retrieved 2023-05-02..
Research
[edit]Hutchinson's research program focuses on the neuroimmune contributions to chronic pain, stress, and depression, with the aim of developing biomarker tools and novel neuroimmune targeted therapies.[1] He has made significant contributions to the field, particularly in the areas of opioids and central immune signaling, TLR4-dependent neuropathic pain, and objective biomarkers of exaggerated pain.[1]
Hutchinson was the first to demonstrate that opioid-induced immune signaling within the brain and spinal cord modifies the analgesic effects of opioids and contributes to atypical pain-producing actions, tolerance, respiratory depression, and withdrawal.[5] He also discovered Toll-Like Receptor 4 (TLR4) as the non-opioid receptor through which this immune signaling occurs, paving the way for the development of novel neuroimmune targeted therapies.[6]
Furthermore, Hutchinson's work on TLR4-dependent neuropathic pain revealed that pharmacological TLR4 blockade could reverse pain behaviors and that female neurosteroids have TLR4 activity, leading to enhanced TLR4 proinflammatory signaling and heightened pain responses in females.[7] He has also created the first clinical model of neuroimmune pain in healthy individuals, allowing for the development of objective biomarkers of persistent pain.[8]
Funding and awards
[edit]Hutchinson's research program has been consistently funded, with over $71.3 million in career funding, including over $54 million from the National Health and Medical Research Council (NHMRC) and the Australian Research Council (ARC).[1] He has received numerous awards, including the Inaugural Coppoc ONE Health Lecture at the College of Veterinary Medicine"New Coppoc ONE Health Lecture to feature renowned international neuroscientist". www.k-state.edu. Retrieved 2023-05-02., Kansas State University, the 2019 Vice-Chancellor's Award for Outstanding Achievement, and the 2015 James McWha Award of Excellence"lumen -- James McWha Award". www.adelaide.edu.au. Retrieved 2023-05-02.
Personal life
[edit]Hutchinson was raised in the Sydney suburb of North Ryde and moved to Adelaide in the mid 1980's.[1] He married Amanda in 2000.[1] Amanda is an Associate Professor in Psychology at the University of South Australia.[1] They have two daughters.[1]
References
[edit]- ^ a b c d e f g h i j k l m n o p q r s t u v w "Prof Mark R Hutchinson". researchers.adelaide.edu.au. Retrieved 2023-05-02.
- ^ "Professor Mark Hutchinson appointmented to the National Science ..." www.adelaide.edu.au. Retrieved 2023-05-02.
- ^ "Meet the AEA Advisory Board - Australia's Economic Accelerator". www.aea.gov.au. Retrieved 2023-05-02.
- ^ "Australia's Economic Accelerator Advisory Board welcomed". scienceandtechnologyaustralia.org.au. Retrieved 2023-05-02.
- ^ Hutchinson, Mark R.; Shavit, Yehuda; Grace, Peter M.; Rice, Kenner C.; Maier, Steven F.; Watkins, Linda R. (2011). "Exploring the Neuroimmunopharmacology of Opioids: An Integrative Review of Mechanisms of Central Immune Signaling and Their Implications for Opioid Analgesia". Pharmacological Reviews. 63 (3): 772–810. doi:10.1124/pr.110.004135. ISSN 0031-6997. PMC 3141881. PMID 21752874.
- ^ Hutchinson, Mark R.; Zhang, Yingning; Brown, Keri; Coats, Benjamen D.; Shridhar, Misha; Sholar, Paige W.; Patel, Sonica J.; Crysdale, Nicole Y.; Harrison, Jacqueline A.; Maier, Steven F.; Rice, Kenner C.; Watkins, Linda R. (2008). "Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)". The European Journal of Neuroscience. 28 (1): 20–29. doi:10.1111/j.1460-9568.2008.06321.x. ISSN 0953-816X. PMC 2536475. PMID 18662331.
- ^ Sorge, Robert E.; LaCroix-Fralish, Michael L.; Tuttle, Alexander H.; Sotocinal, Susana G.; Austin, Jean-Sebastien; Ritchie, Jennifer; Chanda, Mona Lisa; Graham, Andrew C.; Topham, Leah; Beggs, Simon; Salter, Michael W.; Mogil, Jeffrey S. (2011-06-29). "Spinal Toll-Like Receptor 4 Mediates the Early Phase of Both Thermal and Mechanical Hypersensitivity in Chronic Constrictive Injury Neuropathy". The Journal of Pain. 12 (6): 655–662. doi:10.1016/j.jpain.2010.11.003. ISSN 1526-5900. PMC 3125072. PMID 21296025.
- ^ Hutchinson, Mark R.; Buijs, Michiel; Tuke, Jonathan; Kwok, Yuen H.; Gentgall, Melanie; Williams, Desmond; Rolan, Paul (2013). "Low-dose endotoxin potentiates capsaicin-induced pain in man: evidence for a pain neuroimmune connection". Brain, Behavior, and Immunity. 30 (2): 3–11. doi:10.1016/j.bbi.2013.03.002. ISSN 1090-2139. PMC 3566551. PMID 23524167.